2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Uterine Cervical Neoplasms
1
Sarcoma, Ewing
1
Recurrence
1
Ovarian Neoplasms
1
Osteosarcoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma
1
HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer
1
Chondrosarcoma
1
Interventions
Ifosfamide
5
Filgrastim
5
Doxorubicin
5
Gemcitabine
4
Docetaxel
4
Radiotherapy
3
Proton Therapy
3
Carboplatin
3
regorafenib
2
ivosidenib
2
enasidenib
2
belinostat
2
Sunitinib
2
Peripheral Blood Stem Cell Transplantation
2
Nivolumab
2
Immune Checkpoint Inhibitors
2
HhAntag691
2
Fluorouracil
2
Etoposide
2
Epirubicin
2
Cyclophosphamide
2
Cisplatin
2
Chemotherapy, Adjuvant
2
Celecoxib
2
Bevacizumab
2
venetoclax
1
toripalimab
1
temsirolimus
1
tazemetostat
1
tanespimycin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Chondrosarcoma
×
TQ-B3525
×
Clear all
NCT04690725
2020-12-31
TQBSP
Peking University People's Hospital
Phase 1/2
Unknown
29 enrolled